Finasteride

Finasteride blocks the enzyme that converts testosterone to DHT — slowing hair loss and shrinking the prostate. It works well for most men. For a minority, the cost is sexual or mood side effects that can persist after stopping (post-finasteride syndrome).

5-alpha reductase inhibitor (type II selective)Prescription requiredEvidence A
⚠ Not medical advice.Not medical advice. This page is educational. Discuss with your physician before starting, changing, or stopping any medication.

Why it matters

Finasteride is one of the most-studied small-molecule drugs in men's health, and one of the most polarizing. The mechanism is clean: block 5-alpha reductase type II, drop DHT by roughly 65–70%, slow androgenic hair loss, and shrink the BPH prostate. The PCPT trial (Thompson et al., NEJM 2003) showed a 25% reduction in prostate cancer incidence, though it flagged a debated increase in high-grade tumors (later analyses suggest the high-grade signal was a detection artifact). MTOPS (McConnell et al., NEJM 2003) confirmed benefit for BPH symptoms. For hair loss, finasteride is the most effective oral option short of dutasteride. The complication is post-finasteride syndrome (PFS): a constellation of persistent sexual, cognitive, and mood symptoms that some men experience after stopping. Irwig (2012) documented persistent sexual dysfunction in 96% of his case series of young men, Traish (2018) reviewed the mechanism and patient phenotype, and the FDA has updated the Propecia label twice to reflect these reports. PFS is not common — but it is not zero, and it is not psychosomatic. Most men do fine on finasteride. A meaningful minority do not. Informed consent, baseline mood/sexual function documentation, and a low threshold to discontinue at first symptoms are the honest standard of care.

Uses

Label uses (approved)
  • Androgenetic alopecia (male pattern hair loss) — 1 mg/day
  • Benign prostatic hyperplasia (BPH) — 5 mg/day

Dosing

Label dose
1 mg daily (hair loss) or 5 mg daily (BPH)
Off-label / biohacker dose
0.25–0.5 mg daily (low-dose protocol — preserves much of the efficacy with potentially fewer side effects); topical 0.1–0.25%
Titration: Effect on hair plateaus around 3–6 months. PSA roughly halves on finasteride — multiply measured PSA by 2 in men taking it. Stop is reversible for most metrics, but post-finasteride syndrome (PFS) is a real, debated phenomenon.
When to take: Same time daily

Side effects & warnings

Common
  • Reduced libido
  • Erectile dysfunction
  • Reduced ejaculate volume
  • Mild gynecomastia
  • Mood changes
Uncommon but serious
  • Persistent sexual dysfunction (post-finasteride syndrome)
  • Persistent depression
  • Cognitive complaints
  • Suicidal ideation (rare, label warning)
Serious warnings
POST-FINASTERIDE SYNDROME (PFS): A minority of men report sexual, neurological, and mood symptoms that persist for months or years after discontinuation. Mechanisms are debated and prevalence is contested (estimates range from very rare to several percent depending on methodology). The FDA updated the Propecia label in 2011 and again in 2012 to reflect persistent erectile dysfunction, libido changes, and depression/suicidal ideation reports. Pre-existing depression or anxiety raises baseline risk and should prompt extra caution.

Biomarkers affected

dhea s
decrease
Modest reductions reported in some studies; mechanism via altered androgen metabolism. Not a primary monitoring target.
Evidence: weak
total testosterone
increase
Serum T typically rises 10–15% as less substrate is consumed by 5-alpha reductase. Note: PSA roughly halves on finasteride — clinicians DOUBLE measured PSA when interpreting.
Evidence: moderate

Monitoring

Baseline mood / sexual function inventory. Periodic PSA (and DOUBLE the measured value when interpreting). Stop and reassess if sexual or mood symptoms develop.

The honest risk picture

## Realistic risks of finasteride — including post-finasteride syndrome **Acute sexual side effects:** Reduced libido, ED, or decreased ejaculate volume occur in roughly 1.5–4% of men in trial data. Most resolve on discontinuation. **Post-finasteride syndrome (PFS):** A subset of men report sexual, cognitive, and mood symptoms that persist for months or years after stopping. Prevalence estimates vary dramatically (from <0.1% in some industry-funded analyses to several percent in independent surveys). The mechanism is not settled — neurosteroid disruption (reduced allopregnanolone synthesis) is the leading hypothesis. Symptoms reported include persistent ED, anhedonia, brain fog, anxiety, depression, and in severe cases suicidal ideation. The FDA updated the label in 2011 and 2012 to reflect persistent ED, libido changes, and depression/suicidal ideation reports. **Depression and suicidal ideation:** The Propecia label warns of mood changes including suicidal ideation. Men with pre-existing depression or anxiety should approach with extra caution and consider topical or alternatives. **PSA effect:** Finasteride roughly halves measured PSA. When interpreting PSA in a man on finasteride, DOUBLE the value. Missing this leads to delayed prostate cancer diagnosis. **Gynecomastia:** Uncommon but reported, particularly at the 5 mg BPH dose. **Honest framing:** Most men tolerate finasteride well. But the risk of PFS — even if small in absolute terms — is high in impact. Document baseline sexual function and mood. Stop at the first sign of persistent symptoms. Topical or low-dose oral is a reasonable risk-mitigation strategy. The drug works. It is not free.

Practical context

Cost (US, retail)
$25/mo
Legality
Prescription medication in the US. Widely prescribed via telehealth. Topical and low-dose versions typically from compounding pharmacies.
Interactions
false

FAQ

Will finasteride affect my testosterone?+
Modestly. Serum total T typically rises 10–15% (less substrate consumed by 5-alpha reductase) and DHT drops about 65–70%. Free T may rise slightly. Estradiol is usually unchanged or marginally up.
What is post-finasteride syndrome (PFS)?+
PFS describes persistent sexual, neurological, and/or mood symptoms that continue after stopping finasteride. Prevalence is debated and the mechanism is not fully understood (neurosteroid disruption is the leading hypothesis). The FDA has updated the label twice to acknowledge persistent symptom reports. It is not common — but it is real.
Does topical finasteride avoid the side effects?+
Reduced systemic absorption may reduce — not eliminate — risk. Some absorption still occurs and serum DHT can still drop measurably. The data is thinner than for oral, but topical is a reasonable middle ground for risk-averse men.
What about dutasteride?+
Dutasteride blocks both type I and type II 5-AR and suppresses DHT more deeply (>90%). Hair results are slightly better but the side effect profile is similar — and arguably worse for some men, since the suppression is more complete.
References (5)+
  1. Prostate Cancer Prevention Trial (PCPT) — Finasteride 5 mg (Thompson et al., NEJM 2003). . https://pubmed.ncbi.nlm.nih.gov/12824459/
  2. Medical Therapy of Prostatic Symptoms (MTOPS) trial (McConnell et al., NEJM 2003). . https://pubmed.ncbi.nlm.nih.gov/14681504/
  3. Persistent Sexual Side Effects of Finasteride for Male Pattern Hair Loss (Irwig, J Sex Med 2012). . https://pubmed.ncbi.nlm.nih.gov/22364389/
  4. Post-Finasteride Syndrome — Adverse Effects on 5-Alpha Reductase Inhibitors (Traish, F1000Res 2018). . https://pubmed.ncbi.nlm.nih.gov/29744038/
  5. Finasteride and Suicidal Ideation — Pharmacovigilance Review. . https://pubmed.ncbi.nlm.nih.gov/33136107/
The prime report

Weekly performance intelligence.

New studies, protocols, and optimization frameworks delivered every Monday. No fluff, no motivation quotes — only what moves the needle.

No spam. Unsubscribe anytime.